AC Immune (ACIU) Cash from Investing Activities (2015 - 2025)
AC Immune (ACIU) posted quarterly Cash from Investing Activities of $20.0 million for Q4 2025, up 558.45% year-over-year from $3.0 million in Q4 2024, and down 22.36% quarter-over-quarter from $25.8 million in Q3 2025.
AC Immune (ACIU) Cash from Investing Activities (2015 - 2025) Analysis & Trends
AC Immune (ACIU) has reported Cash from Investing Activities for 11 consecutive years, with $20.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 558.45% year-over-year to $20.0 million; the TTM figure through Dec 2025 stood at $78.0 million (up 166.34% YoY), while the FY2025 annual figure was $76.6 million, up 163.77% from the prior year.
- Cash from Investing Activities declined to $20.0 million in Q4 2025 per ACIU's latest filing, from $25.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $46.3 million in Q1 2023 and bottomed at -$83.8 million in Q2 2024.
- Historically, Cash from Investing Activities has averaged -$69004.6 across 5 years, with a median of -$561917.7 in 2021.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 8013.88% — and 2024, when it tumbled 1362.29%.
- AC Immune's Cash from Investing Activities stood at -$23.6 million in 2021, then jumped by 121.85% to $5.1 million in 2022, then jumped by 409.85% to $26.2 million in 2023, then tumbled by 116.64% to -$4.4 million in 2024, then jumped by 558.45% to $20.0 million in 2025.
- Business Quant data shows ACIU's Cash from Investing Activities at $20.0 million in Q4 2025, $25.8 million in Q3 2025, and $28.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.02 Mn |
| Dec 31, 2025 | 20.02 Mn |
| Sep 30, 2025 | 25.79 Mn |
| Sep 30, 2025 | 25.79 Mn |
| Jun 30, 2025 | 28.85 Mn |
| Jun 30, 2025 | 28.85 Mn |
| Mar 31, 2025 | 3.37 Mn |
| Mar 31, 2025 | 3.37 Mn |
| Dec 31, 2024 | -4.37 Mn |
| Dec 31, 2024 | -4.37 Mn |
| Sep 30, 2024 | -2.41 Mn |
| Sep 30, 2024 | -2.41 Mn |
| Jun 30, 2024 | -83.84 Mn |
| Jun 30, 2024 | -83.84 Mn |
| Mar 31, 2024 | -26.99 Mn |
| Mar 31, 2024 | -26.99 Mn |
| Dec 31, 2023 | 26.24 Mn |
| Dec 31, 2023 | 26.24 Mn |
| Sep 30, 2023 | 5.34 Mn |
| Sep 30, 2023 | 5.34 Mn |